SynBioBeta Speaker

Kirsten Engel

SecureDNA

Dir. Strat. Partnerships & Client Rel.

Kirsten Engel leads global strategic partnerships and clientengagement for the SecureDNA Foundation, a Swissnonprofit dedicated to safeguarding biotechnology throughfree, privacy-preserving DNA synthesis screening.SecureDNA provides free, ultra-fast, privacy-preservingDNA synthesis screening to detect regulated, controlled, orhazardous sequences, and is the only system that alsoscreens millions of predicted functional variants to preventevasion. The platform has been adopted by providersacross North America, Europe, and Asia, and uniquelycombines ultra-sensitive detection (down to 30 base pairs)with flexible integration for both commercial and benchtopsynthesis.In addition to supporting synthesis providers and benchtop manufacturers, Kirsten represents SecureDNA in international policy discussions and working groups, helping shape emerging best practices for responsible DNA synthesis oversight. She isparticularly focused on building international collaboration to close global screening gaps and ensure equitable access to security infrastructure. Kirsten’s work builds on a background spanning business development, international marketing and engagement, nonprofit partnerships, and strategic communications. AtSecureDNA, she is advancing the mission of making DNA synthesis both safe and accessible worldwide, with a vision of preventing misuse while enabling legitimate research to thrive.

Sessions Featuring

Kirsten

This Year

Breakout Session

•

4:30 PM

-

5:15 PM

Business of Biology

Synthesis Screening in the Age of Powerful AI

As AI reshapes what's possible in biology, biosecurity needs to keep up. Nucleic acid synthesis screening, which checks what's being ordered and by whom, is one of the field's most important lines of defense. But as AI capabilities advance, the screening infrastructure needs to evolve with them. This panel brings together leaders from the Sequence Biosecurity Risk Consortium, Fourth Eon Bio, SecureDNA, and BioTrust to discuss how sequence and customer screening are adapting to a new threat landscape.

Featuring

Jacob Beal

RTX BBN Technologies

Engineering Fellow

Gary Abel

Fourth Eon Bio

Principal Scientist

Kirsten Engel

SecureDNA

Dir. Strat. Partnerships & Client Rel.

Jonas Sandbrink

Sentinel Bio

Entrepreneur-in-Residence

Tessa Alexanian

IBBIS

Technical Lead

Breakout Session

•

4:30 PM

-

5:15 PM

Business of Biology

Synthesis Screening in the Age of Powerful AI

As AI reshapes what's possible in biology, biosecurity needs to keep up. Nucleic acid synthesis screening, which checks what's being ordered and by whom, is one of the field's most important lines of defense. But as AI capabilities advance, the screening infrastructure needs to evolve with them. This panel brings together leaders from the Sequence Biosecurity Risk Consortium, Fourth Eon Bio, SecureDNA, and BioTrust to discuss how sequence and customer screening are adapting to a new threat landscape.

Featuring

Jacob Beal

RTX BBN Technologies

Engineering Fellow

Gary Abel

Fourth Eon Bio

Principal Scientist

Kirsten Engel

SecureDNA

Dir. Strat. Partnerships & Client Rel.

Jonas Sandbrink

Sentinel Bio

Entrepreneur-in-Residence

Tessa Alexanian

IBBIS

Technical Lead

Previous Speakers Include